Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab and LNA043 in knee osteoarthritis
NCT04814368Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of LNA043 in knee osteoarthritis (OA), sponsored by Novartis. Started Aug 2021; status: terminated.
02
Drugs
LNA043
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04814368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814368.